May 10, 2021, 13:54 PM IST
New Delhi: 2-deoxy-D-glucose (2-DG), the anti-COVID-19 drug that has been developed by Defence Research and Development Organisation (DRDO) and been given an emergency use nod by Drugs Controller General of India s (DCGI), was first studied by Patanjali researchers, claimed Acharya Balkrishna on Sunday (May 9, 2021).
A day after the DCGI granted permission for the Emergency Use of this drug as an adjunct therapy in moderate to severe COVID-19 patients, Acharya Balkrishna said, We take immense pride that Patanjali has been the pioneer centre-stone for most of the researches conducted for COVID-19.
Balkrishna, MD of Patanjali Ayurved Ltd and co-founder of Patanjali Yogpeeth in Haridwar, also shared a picture of his research paper, co-authored with three other researchers.
by Bhaswati Guha Majumder - May 10, 2021 05:28 AM
Yoga guru Ramdev and Patanjali CEO Balkrishna
Snapshot
Researchers from Patanjali Research Institute, along with experts from Vivekanand Education Societyâs Institute of Technology and Jain Vishva Bharati Institute, published their findings in 2020.
With the country battling the second wave of coronavirus, the Drugs Controller General of India (DCGI) on 8 May approved a drug for emergency use.
The drug is 2-deoxy-D-glucose (2-DG) which has been approved as an adjunct therapy in moderate-to-severe Covid-19 cases. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty, said the Defence Research and Development Organisation (DRDO).
India s COVID-19 Cases Rise By Over 400,000 Despite Lockdowns
India s total COVID-19 cases rose by over 400,000 for the fourth consecutive day on Sunday even as several states imposed strict lockdowns to curb the spread of the virus.
India s health ministry reported 4,092 fatalities over the past 24 hours, taking the overall death toll to 242,362. Cases rose by 403,738, increasing the total since the start of the pandemic to 22.3 million.
India on Saturday reported its highest ever single-day COVID-19 death toll, as cases continued to rise and states imposed stricter lockdowns.
India s health ministry reported 4,187 fatalities over the past 24 hours, taking the overall death toll close to 240,000. The Institute for Health Metrics and Evaluation estimates that India will see 1 million COVID deaths by August.
Reuters Reuters
9 May, 2021, 3:15 pm
A man walks past burning pyres with people who died from the coronavirus disease (COVID-19), on the banks of the river Ganges at Garhmukteshwar in the northern state of Uttar Pradesh, India, May 6, 2021. REUTERS/Danish Siddiqui
India on Saturday reported its highest ever single-day COVID-19 death toll, as cases continued to rise and states imposed stricter lockdowns.
India’s health ministry reported 4,187 fatalities over the past 24 hours, taking the overall death toll close to 240,000. The Institute for Health Metrics and Evaluation estimates that India will see 1 million COVID deaths by August.
Cases rose by 401,078 on Saturday, bringing the total since the start of the pandemic to 21.9 million.
India s COVID-19 Cases Rise By Over 400,000 Despite Lockdowns
India s total COVID-19 cases rose by over 400,000 for the fourth consecutive day on Sunday even as several states imposed strict lockdowns to curb the spread of the virus.
India s health ministry reported 4,092 fatalities over the past 24 hours, taking the overall death toll to 242,362. Cases rose by 403,738, increasing the total since the start of the pandemic to 22.3 million.
India on Saturday reported its highest ever single-day COVID-19 death toll, as cases continued to rise and states imposed stricter lockdowns.
India s health ministry reported 4,187 fatalities over the past 24 hours, taking the overall death toll close to 240,000. The Institute for Health Metrics and Evaluation estimates that India will see 1 million COVID deaths by August.